Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Stryer Biotech
WARNING LETTER
•Stryer Biotech•October 18, 2007

Stryer Biotech – FDA Warning Letter, Oct 18, 2007

Record Details

On April 25, 2008, the FDA issued a Warning Letter to Stryker Biotech following a September-October 2007 inspection of their Hopkinton, MA facility, which manufactures Calstrux, OP-1 Implant, and OP-1 Putty. The inspection revealed significant violations of the Federal Food, Drug, and Cosmetic Act and Quality System (QS) regulation.

A primary violation was the failure to obtain an Investigational Device Exemption (IDE) before initiating clinical investigations of the OP-1 Implant for new, unapproved indications (in combination with other substances). This rendered the devices adulterated under section 501(f)(1)(B) and misbranded under section 502(o) due to lack of premarket approval (PMA) or IDE, and failure to submit a 510(k) notification for the new intended use.

Additional QS regulation violations (21 CFR Part 820) included: 1. Failure to adequately establish and maintain procedures for analyzing quality data (e.g., complaints, CAPA), specifically lacking clear definitions for "trending" and "statistical methods," leading to inadequate complaint analysis. The firm's response was deemed inadequate as the new procedure's trending definition was too broad to detect significant increases in complaints. 2. Failure to adequately implement changes for corrective actions (e.g., Corporate CAPA #2006-0

Company
Stryer Biotech
Inspection date
October 18, 2007
Product type
Devices
Office
New England District Office
People
  • William S. Boivin (Retired at FDA)
  • James E. Kemler
  • Stephen P. MacMillan
View Company Profile

ID · d041302d-866c-4315-baea-dd39badcc32e

Violation Codes10
FD&C Act 502(o)FD&C Act 509(t)(2)FD&C Act 510(k)FD&C Act 511(f)(1)(B)FD&C Act 515(a)FD&C Act 520(g)FD&C Act 801(a)(3)21 U.S.C. 321(h)21 CFR 812.20(a)(2)21 CFR 812.40

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Stryer Biotech
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.